What is the current role of immunotherapy in EGFR mutant advanced NSCLC?

Lung Cancer. 2022 Apr:166:253-254. doi: 10.1016/j.lungcan.2021.12.001. Epub 2021 Dec 24.

Authors

Maria A Velez¹, Hsin Hsiang Clarence Tsai¹, David B Shackelford¹, Edward B Garon¹, Aaron Lisberg²

Affiliations

¹ Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.
² Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA. Electronic address: alisberg@mednet.ucla.edu.

PMID: 35031176
DOI: 10.1016/j.lungcan.2021.12.001

No abstract available

Publication types

Editorial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

Carcinoma, Non-Small-Cell Lung* / genetics
Carcinoma, Non-Small-Cell Lung* / therapy
ErbB Receptors / genetics
Humans
Immunotherapy
Lung Neoplasms* / genetics
Lung Neoplasms* / therapy
Mutation / genetics

Substances

EGFR protein, human
ErbB Receptors

Grants and funding